Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 101

Sort by

Sort Order Select

Journal Articles

Attrition after Referral for Chimeric Antigen Receptor T-Cell (CAR-T) Products in Multiple Myeloma (MM)

Blood (2023) 142 (Supplement 1): 3794.

https://doi.org/10.1182/blood-2023-187583

Published: 2023

Journal Articles

Single Cell Multi-Omic Analysis of Tumor Microenvironment Evolution across the Disease Spectrum of Multiple Myeloma Identifies Differential Mechanisms of Immune Suppression

Minghao Dang, Hima Bansal, Maria Jose Acevedo-Calado, Li Qin, Wei Tan, Luz Yurany Moreno Moreno Rueda, Mei Huang, David Berrios Nolasco, Hans C. Lee, Krina K. Patel, Pei Lin, Sheeba K. Thomas, Donna M. Weber, Linghua Wang, Elisabet E. Manasanch, Robert Z. Orlowski

Blood (2023) 142 (Supplement 1): 89.

https://doi.org/10.1182/blood-2023-182902

Published: 2023

Journal Articles

Impact of Pre-Transplant Minimal Residual Disease in Patients with Multiple Myeloma with ≥ Very Good Partial Response Receiving Autologous Hematopoietic Stem Cell Transplantation

Blood (2023) 142 (Supplement 1): 2215.

https://doi.org/10.1182/blood-2023-173040

Published: 2023

Journal Articles

Safety and Efficacy Outcomes for Patients with High-Risk Multiple Myeloma Receiving Idecabtagene Vicleucel: The MD Anderson Experience

Oren Pasvolsky, Michelle Hildebrandt, Naveen Subramanian, Christopher Ferreri, Hans C. Lee, Elisabet E. Manasanch, Sheeba K. Thomas, Donna M. Weber, Mahmoud Gaballa, Christen Dillard, Melody Becnel, Chitra Hosing, Pei Lin, Behrang Amini, Muzaffar H. Qazilbash, Nilesh Kalariya, Robert Z. Orlowski, Krina K. Patel

Blood (2023) 142 (Supplement 1): 4712.

https://doi.org/10.1182/blood-2023-187854

Published: 2023

Journal Articles

Lysosomal Associated Membrane Protein Family Member 5 (LAMP5) As a Novel Mediator of, and Target in High Risk Multiple Myeloma (MM)

Hua Wang, Luz Yurany Moreno Rueda, Minghao Dang, Luz Yurany Moreno Rueda, Hans C. Lee, Krina K. Patel, Sheeba K. Thomas, Donna M. Weber, Elisabet E. Manasanch, David E. Symer, Robert Z. Orlowski

Blood (2023) 142 (Supplement 1): 873.

https://doi.org/10.1182/blood-2023-189286

Published: 2023

Journal Articles

Impact of Revised International Staging System 2 (R2-ISS) Risk Stratification on Outcomes of Patients with Multiple Myeloma Receiving Autologous Hematopoietic Stem Cell Transplantation

Blood (2023) 142 (Supplement 1): 3356.

https://doi.org/10.1182/blood-2023-174558

Published: 2023

Journal Articles

Trends in Outcomes over Three Decades after Upfront Autologous Stem Cell Transplant for Multiple Myeloma at MD Anderson Cancer Center

Blood (2023) 142 (Supplement 1): 4962.

https://doi.org/10.1182/blood-2023-174479

Published: 2023

Journal Articles

Outcomes of Patients with Multiple Myeloma and 1q Gain/Amplification Receiving Autologous Hematopoietic Stem Cell Transplant: The MD Anderson Cancer Center Experience

Blood (2023) 142 (Supplement 1): 4963.

https://doi.org/10.1182/blood-2023-173697

Published: 2023

Journal Articles

Initial Clinical Results and Immune Correlates of a Phase 2 Study of Daratumumab, Bortezomib, Dexamethasone Followed By a Proteasome Inhibitor in -Class Transition ( i CT) to Daratumumab, Ixazomib, Dexamethasone in Relapsed Refractory Multiple Myeloma

Hans C. Lee, June Li, Heather Lin, Astrid D. Murga, Gabriela M Rodriguez, Mostafa E. Mohamed, Jared Henderson, Sarah Rodriguez, Melody R. Becnel, Donna M. Weber, Swami P. Iyer, Gregory P. Kaufman, Sheeba K. Thomas, Elisabet E. Manasanch, Krina K. Patel, Stephen J. Noga, Michael R. Green, Robert Z. Orlowski, Cara L Haymaker

Blood (2023) 142 (Supplement 1): 4760.

https://doi.org/10.1182/blood-2023-188201

Published: 2023

Journal Articles

Daratumumab-Based Maintenance in Patients with Relapsed Multiple Myeloma after Salvage Autologous Hematopoietic Stem Cell Transplantation

Blood (2023) 142 (Supplement 1): 7070.

https://doi.org/10.1182/blood-2023-189109

Published: 2023

Journal Articles

Single Cell Multi-Omic Analysis of Neoplastic Plasma Cells across the Disease Spectrum Identifies Novel Pathobiologic Mediators and Potential Therapeutic Targets in Multiple Myeloma (MM)

Luz Yurany Moreno Rueda, Keiko Akagi, Amishi U. Vora, Hans C. Lee, Krina K. Patel, Pei Lin, Bo Jiang, Yang Song, Maura L. Gillison, Sheeba K. Thomas, Donna M. Weber, Lixia Diao, Jing Wang, Elisabet E. Manasanch, David E. Symer, Robert Z. Orlowski

Blood (2023) 142 (Supplement 1): 752.

https://doi.org/10.1182/blood-2023-188016

Published: 2023

Journal Articles

Initial Results of a Phase 1 Study of Daratumumab, Ixazomib, and Dexamethasone in Newly Diagnosed and Previously Treated AL Amyloidosis

Hans C. Lee, Gregory P. Kaufman, Lei Feng, Astrid Murga, Ralph J. Johnson, Donna M. Weber, Sheeba K Thomas, Qaiser Bashir, Muzaffar H Qazilbash, Swaminathan P. Iyer, Krina Patel, Melody R. Becnel, Elisabet E. Manasanch, Robert Z. Orlowski

Blood (2022) 140 (Supplement 1): 4428–4430.

https://doi.org/10.1182/blood-2022-167555

Published: 2022

Journal Articles

Single Cell Profiling of BCMA Naïve Vs Refractory Relapsed Myeloma Patients Reveals Unique Transcriptomic Profiles in Tumor and Microenvironment

Minghao Dang, Li Qin, Wei Tan, Liping Dong, Hans C. Lee, Krina Patel, Luz Yurany Moreno Rueda, Pei Lin, Hima Bansal, David Berrios, Sheeba K Thomas, Donna M. Weber, David E. Symer, Linghua Wang, Elisabet E. Manasanch, Robert Z. Orlowski

Blood (2022) 140 (Supplement 1): 7122–7124.

https://doi.org/10.1182/blood-2022-165540

Published: 2022

Journal Articles

Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Translocation (4:14): The MD Anderson Cancer Center Experience

Oren Pasvolsky, Denái R Milton, Adeel Masood, Sophiya S Shehzad, Mark R Tanner, Qaiser Bashir, Samer A Srour, Neeraj Saini, Jeremy L. Ramdial, Yago Nieto, Hans C. Lee, Krina Patel, Partow Kebriaei, Sheeba K Thomas, Donna M. Weber, Robert Z. Orlowski, Elizabeth J Shpall, Richard E Champlin, Muzaffar H Qazilbash

Blood (2022) 140 (Supplement 1): 10589–10591.

https://doi.org/10.1182/blood-2022-162465

Published: 2022

Journal Articles

Impact of Presence and Amount of Clonal Plasma Cells in Autografts Affect Outcomes in High-Risk Multiple Myeloma Patients Undergoing Autologous Hematopoietic Stem Cell Transplant

Blood (2022) 140 (Supplement 1): 284–286.

https://doi.org/10.1182/blood-2022-157960

Published: 2022

Journal Articles

Safety and Efficacy of Combination Maintenance Therapy with Ixazomib and Lenalidomide in Post-Transplant Myeloma Patients

Krina K. Patel, Jatin J. Shah, Lei Feng, Hans C. Lee, Elisabet E. Manasanch, Jasper B. Olsem, Ashley N. Morphey, Xiao Jiao Huo, Qaiser Bashir, Sheeba K Thomas, Muzaffar H. Qazilbash, Donna M. Weber, Robert Z. Orlowski

Blood (2021) 138 (Supplement 1): 4774.

https://doi.org/10.1182/blood-2021-151950

Published: 2021

Journal Articles

Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma

Blood (2020) 136 (Supplement 1): 22.

https://doi.org/10.1182/blood-2020-141261

Published: 2020

Journal Articles

Outcomes in Patients with AL (Light-Chain) Cardiac Amyloidosis

Jeremy L. Ramdial, MD, Mahmoud R. Gaballa, MD, Taha Al-Juhaishi, MD, Qaiser Bashir, MD, Samer A. Srour, MD MS, Neeraj Saini, MD, Yago Nieto, MD, Chitra Hosing, MD, Uday R. Popat, MD, Regan Murphy, PA-C, Hans C. Lee, MD, Krina K. Patel, MD, Elisabet E. Manasanch, MD, Sheeba K. Thomas, MD, Donna M. Weber, MD, Gregory P. Kaufman, MD, Robert Z. Orlowski, MDPhD, Richard E. Champlin, MD, Muzaffar H. Qazilbash, MD

Blood (2020) 136 (Supplement 1): 11–13.

https://doi.org/10.1182/blood-2020-143209

Published: 2020

Journal Articles

Outcomes of Patients with Multiple Myeloma Who Received VRD Induction, Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance

Mahmoud R. Gaballa, MD, Taha Al-Juhaishi, MD, Qaiser Bashir, MD, Samer A. Srour, MD MS, Neeraj Saini, MD, Jeremy Ramdial, MD, Yago Nieto, MD, Regan Murphy, PA-C, Hans C. Lee, MD, Krina K. Patel, MD, Partow Kebriaei, MD, Sheeba K. Thomas, MD, Donna M. Weber, MD, Robert Z. Orlowski, MDPhD, Richard E. Champlin, MD, Muzaffar H. Qazilbash, MD

Blood (2020) 136 (Supplement 1): 14–15.

https://doi.org/10.1182/blood-2020-135865

Published: 2020

Journal Articles

Extensive Changes of the Immune Microenvironment Are Associated with Progression from Precursor Stages to Multiple Myeloma

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-137555

Published: 2020

NARROW

Attrition after Referral for Chimeric Antigen Receptor T-Cell (CAR-T) Products in Multiple Myeloma (MM)

Single Cell Multi-Omic Analysis of Tumor Microenvironment Evolution across the Disease Spectrum of Multiple Myeloma Identifies Differential Mechanisms of Immune Suppression

Impact of Pre-Transplant Minimal Residual Disease in Patients with Multiple Myeloma with ≥ Very Good Partial Response Receiving Autologous Hematopoietic Stem Cell Transplantation

Safety and Efficacy Outcomes for Patients with High-Risk Multiple Myeloma Receiving Idecabtagene Vicleucel: The MD Anderson Experience

Lysosomal Associated Membrane Protein Family Member 5 (LAMP5) As a Novel Mediator of, and Target in High Risk Multiple Myeloma (MM)

Impact of Revised International Staging System 2 (R2-ISS) Risk Stratification on Outcomes of Patients with Multiple Myeloma Receiving Autologous Hematopoietic Stem Cell Transplantation

Trends in Outcomes over Three Decades after Upfront Autologous Stem Cell Transplant for Multiple Myeloma at MD Anderson Cancer Center

Outcomes of Patients with Multiple Myeloma and 1q Gain/Amplification Receiving Autologous Hematopoietic Stem Cell Transplant: The MD Anderson Cancer Center Experience

Initial Clinical Results and Immune Correlates of a Phase 2 Study of Daratumumab, Bortezomib, Dexamethasone Followed By a Proteasome Inhibitor in -Class Transition ( i CT) to Daratumumab, Ixazomib, Dexamethasone in Relapsed Refractory Multiple Myeloma

Daratumumab-Based Maintenance in Patients with Relapsed Multiple Myeloma after Salvage Autologous Hematopoietic Stem Cell Transplantation

Single Cell Multi-Omic Analysis of Neoplastic Plasma Cells across the Disease Spectrum Identifies Novel Pathobiologic Mediators and Potential Therapeutic Targets in Multiple Myeloma (MM)

Initial Results of a Phase 1 Study of Daratumumab, Ixazomib, and Dexamethasone in Newly Diagnosed and Previously Treated AL Amyloidosis

Single Cell Profiling of BCMA Naïve Vs Refractory Relapsed Myeloma Patients Reveals Unique Transcriptomic Profiles in Tumor and Microenvironment

Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Translocation (4:14): The MD Anderson Cancer Center Experience

Impact of Presence and Amount of Clonal Plasma Cells in Autografts Affect Outcomes in High-Risk Multiple Myeloma Patients Undergoing Autologous Hematopoietic Stem Cell Transplant

Safety and Efficacy of Combination Maintenance Therapy with Ixazomib and Lenalidomide in Post-Transplant Myeloma Patients

Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma

Outcomes in Patients with AL (Light-Chain) Cardiac Amyloidosis

Outcomes of Patients with Multiple Myeloma Who Received VRD Induction, Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance

Extensive Changes of the Immune Microenvironment Are Associated with Progression from Precursor Stages to Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only